Dr. George Wilding

Dr. George Wilding, MD, is an accomplished medical oncologist and cancer researcher specializing in prostate cancer and genitourinary malignancies. He currently serves as Vice President for Cancer Prevention and Population Sciences at MD Anderson Cancer Center, where he plays a key role in advancing both clinical and translational research initiatives. Dr. Wilding earned his medical degree from the University of Massachusetts Medical School, completed his residency in internal medicine at the University of Massachusetts Medical Center, and his fellowship in medical oncology at Dana-Farber Cancer Institute. He is board-certified in Internal Medicine and Medical Oncology.

Dr. Wilding’s research has focused on androgen receptor signaling, prostate cancer chemoprevention, and novel therapeutic strategies for advanced prostate cancer. He has led multiple clinical trials evaluating targeted therapies and hormone manipulation approaches, contributing significantly to the understanding of disease biology and treatment resistance. His work in chemoprevention has explored agents such as selenium and vitamin E, as well as pharmacologic inhibitors, in an effort to reduce prostate cancer incidence and progression.

In addition to his research, Dr. Wilding has been deeply involved in academic leadership and mentorship. He previously served as Director of the University of Wisconsin Carbone Cancer Center, where he oversaw major expansions in research programs and infrastructure. He has authored numerous peer-reviewed publications, served on national committees, and contributed to shaping cancer prevention strategies at the national level. Through his leadership and scientific expertise, Dr. George Wilding has advanced the field of prostate cancer research and prevention.